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SUMMARY 
 
The nuclear retinoic acid (RA) receptor alpha (RARα) is a transcriptional transregulator 
that controls the expression of specific gene subsets through binding at response elements and 
dynamic interactions with coregulators, which are coordinated by the ligand. Here, we 
highlighted a novel paradigm in which the transcription of RARα-target genes is controlled 
by phosphorylation cascades initiated by the rapid RA activation of the p38MAPK/MSK1 
pathway. We demonstrate that MSK1 phosphorylates RARα at S369 located in the Ligand 
Binding Domain, allowing the binding of TFIIH and thereby phosphorylation of the N-
terminal domain at S77 by cdk7/cyclin H. MSK1 also phosphorylates Histone H3 at S10. 
Finally, the phosphorylation cascade initiated by MSK1 is required for the recruitment of 
RARα/TFIIH complexes to response elements and subsequently for RARα target genes 
activation. Cancer cells characterized by a deregulated p38MAPK/MSK1 pathway, do not 
respond to RA, outlining the essential contribution of the RA-triggered phosphorylation 
cascade in RA signaling. 
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INTRODUCTION 
Nuclear Retinoic Acid (RA) receptors (RARs) consist of three subtypes, α (NR1B1), β 
(NR1B2) and γ (NR1B3) 1-3 which function as ligand-dependent transcriptional regulators 
heterodimerized with Retinoid X Receptors (RXRs). The basic mechanism for transcriptional 
regulation by RARs relies on binding to specific response elements (RAREs) located in the 
promoters of target genes and on ligand-induced structural rearrangements in the Ligand 
Binding Domain (LBD) that direct the association/dissociation of coregulator complexes with 
different enzymatic activities including Histone Acetyltransferases/Deacetylases, Histone 
Methyltransferases/Demethylases, Kinases/Phosphatases, Ubiquitin-ligases/deubiquitinases or 
DNA-dependent ATPases 4-6. The exchanges between coregulatory complexes and RARs are 
dynamic and coordinated 7,8. In fine, they cooperate to alter the chromatin structure 
surrounding the promoter of target genes, paving the way for the recruitment of the 
transcription machinery including RNA Polymerase II and the General Transcription Factors 
9.  
A concept that developed over the last several years is that RARs are subject to 
phosphorylations 10,which play an important and ever-growing role in the transcription of RA-
target genes 11-14. However, the process appeared to be complex and nothing is known about 
the upstream kinases that govern RAR phosphorylation in response to RA and how RARs 
phosphorylation impacts the transcription of target genes. Because p38MAPK is activated in 
response to RA 15-17, we explored whether there is a connection between this kinase signaling 
pathway, RARα phosphorylation and the induction of RARα-target genes.  
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RESULTS 
RA activates p38MAPK leading to MSK1 activation.  
In Mouse Embryo Fibroblasts (MEF), p38MAPK was activated within minutes 
following RA treatment. This activation was transient as it peaked at 15 min and was reversed 
at 60 min (Fig. 1a). P38MAPK was similarly activated by a synthetic RARα agonist but not 
by RARγ and RARβ agonists nor by RARα antagonists (Fig. 1a). P38MAPK activation was 
not observed in MEF knockout for the three RARs, MEF (RARα,β,γ)-/- 18,19, but was restored 
upon reexpression of RARαWT (Fig. 1b), indicating that activation of p38MAPK requires 
liganded RARα. P38MAPK was also rapidly activated in human breast cancer cell lines, such 
as MCF7 cells, but not in SKBR3 cells (Fig. 1c). 
Downstream of p38MAPK, there is MSK1 20 which contributes to the regulation of the 
expression of several genes 21,22. After RA treatment of MCF7 cells and MEFs, there was an 
increase in the activated, phosphorylated form of MSK1 which paralleled the increase in 
phosphorylated p38MAPK (Fig. 1d,e). Activation of MSK1 was inhibited upon knockdown 
of p38MAPK with specific siRNA (Fig. 1f) or by SB203580, a selective inhibitor of 
p38MAPK (data not shown), corroborating that activation of MSK1 occurs downstream of 
p38MAPK in RA signaling. Accordingly, MSK1 was not activated in SKBR3 cells, which are 
defective in RA induction of p38MAPK (Fig.1e). Other signaling pathways that have been 
shown to participate in hormone signaling such as Erks and the cAMP/PKA pathways were 
not activated after RA treatment (data not shown).  
 
RA-activated MSK1 phosphorylates RARα at S369, in vivo. 
Then we wondered if the rapid and transient RA activation of the p38MAPK/MSK1 
pathway was associated with a change in the phosphorylation status of RARα. The RARα 
protein can be phosphorylated at two serine residues, S77 and S369 located in the N- and C-
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terminal domains respectively 10 (Fig. 2a). S77 is phosphorylated by the CAK subcomplex of 
the general transcription factor TFIIH either in vitro (Fig. 2b) or in vivo 11,23. However the 
kinase that phosphorylates in vivo S369, in response to RA, has not yet been identified. S369 
belongs to an Arg-Lys rich motif which corresponds to a consensus phosphorylation site for 
several kinases including MSK1 (Fig. 2a). In in vitro phosphorylation experiments, active 
recombinant MSK1 phosphorylated purified bacterially expressed RARα at S369 (and not at 
S77), as assessed by immunoblotting with antibodies recognizing specifically RARα 
phosphorylated at these residues. (Fig. 2b).  
We also analyzed the in vivo phosphorylation of endogenous RARα in MCF7 cells, 
after PhosphoProtein affinity purification. The amount of phosphorylated RARα markedky 
increased at 5-30 min and decreased 60 min after RA treatment (Fig. 2c), in parallel to the 
activation of p38MAPK/MSK1. This increase in RARα phosphorylation concerned S369 
(Fig. 2d). It was inhibited upon knockdown of MSK1 (Fig. 2e) and did not occur in SKBR3 
cells, which are defective in MSK1 activation (Fig. 2d), highlighting the importance of the 
initial RA activation of MSK1 in RARα phosphorylation at S369.  
 
In vivo, S369 phosphorylation directs RARα interaction with TFIIH and thereby 
S77 phosphorylation.  
RARα was also rapidly phosphorylated at S77 after RA addition (Fig. 2d). 
Unexpectedly, though S77 was not a target for MSK1, phosphorylation of this residue was 
inhibited by SB203580 and by siRNA against MSK1 (Fig. 2e and data not shown). Therefore, 
we wondered if phosphorylation of S77 might be controled by that of S369.  
MEF expressing RARα either WT, S77A or S369A, as the sole RA-dependent 
transcriptional activator in a (RARα,β,γ)-/- background were generated and compared for 
RARα phosphorylation at 5 min intervals following RA addition. In each rescue cell line, 
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MEF(RARαWT), MEF(RARαS369A) and MEF(RARαS77A), the RARα protein was 
expressed at similar amounts (Fig. 2f) and the p38MAPK/MSK1 pathway was similarly 
activated in response to RA (Supplemental information, Fig. S1a). In RA-treated 
MEF(RARαWT), the amount of RARα  phosphorylated at S369 and S77 also increased 
rapidly at 5-15 min (Fig. 2g, lanes 1-4), and was abrogated upon MSK1 knockdown (data not 
shown). In MEF(RARαS369A) (Fig. 2g, lanes 5-8) and MEF(RARαS77A) (Fig. 2g, lanes 9-
12), no signal was obtained by immunoblotting with the antibodies recognizing specifically 
RARα phosphorylated at S369 and S77 respectively, validating their specificity. In 
MEF(RARαS77A), the ability of RARα to be phosphorylated at S369 was not affected, while 
in MEF(RARαS369A), RARα was not phosphorylated at S77. This indicates that 
phosphorylation of S369 controls that of S77 and not vice-versa.  
S369 is located in the LBD, in Loop 9-10 in close proximity to the binding domain of 
cyclin H (Loop 8-9 and the beginning of H9) 24, which forms with cdk7 and MAT1 the CAK 
subcomplex of TFIIH that phosphorylates RARα at S77 11,23. Therefore we hypothesized that, 
in vivo, the RA-induced phosphorylation of S369 would be the signal allowing the interaction 
of RARα with TFIIH and subsequently phosphorylation of S77 by cdk7.  
With that aim, RARα phosphorylation and interaction with TFIIH were analyzed in 
ChIP-Western experiments performed with the MEF(RARαWT), MEF(RARαS369A) or 
MEF(RARαS77A) rescue lines, at 5 min intervals following RA addition (Fig. 2h). In the 
absence of RA, immunoprecipitated RARαWT was not phosphorylated and did not retain 
TFIIH (lane 1). As soon as 5 min following RA addition, RARαWT became phosphorylated 
at S369. Then, at 10 min, RARα interacted with TFIIH and became phosphorylated at S77. 
RARα phosphorylation and interaction with TFIIH were maintained up to 50 min and then 
decreased at 60 min. RARαS77A retained the ability to be phosphorylated at S369 and to 
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recruit TFIIH. In contrast, RARαS369A was unable to interact with TFIIH and was not 
phosphorylated at S77, indicating that, in vivo, phosphorylation of S369 promotes TFIIH 
binding and thereby S77 phosphorylation. Similar results were obtained in 
immunoprecipitation experiments performed with cyclin H antibodies (Supplemental 
information, Fig.S1b). 
 
The integrity of the p38MAPK/MSK1 pathway and of the RARα phosphorylation 
sites are required for the RA induction of RARα-target genes.  
We next asked whether activation of MSK1 is significant for the activation of RARα-
target genes. In MCF7 cells and MEFs, RA treatment enhances transcription of the Cyp26A1 
gene which is the paradigm of the RA-target genes, as assessed by qRT-PCR (Fig. 3a,b). No 
activation of Cyp26A1 was observed upon knockdown of MSK1 (Fig. 3c,d) or in SKBR3 
cells which are refractory to MSK1 activation (Fig. 3b) highlighting the significance of MSK1 
activation for RA induction of RARα-target genes. 
The RA-induced activation of CYP26A1 was also abrogated in MEFs in which all 
RARs have been deleted, but was reestablished upon reintroduction of RARαWT (Fig. 3a). 
However, the RA response was not restored upon reintroduction of the RARαS369A and 
RARαS77A mutants (Fig.3a), indicating that phosphorylation of S77 and S369 is also 
required for RARα-mediated transcription.  
 
Upon RA treatment, RARα is recruited with TFIIH to the promoter of the 
Cyp26A1 gene.  
Next we used chromatin immunoprecipitation (ChIP) experiments to gain mechanistic 
insight into the role of MSK1 activation and/or RARα phosphorylation in the activation of 
Cyp26A1 expression. The CYP26A1 gene promoter contains two functional DR5 RAREs, a 
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proximal one (R1) and a more distal one (R2) (Fig. 4a), which work synergistically in vivo, to 
provide a maximal response to RA 25,26. We assessed the RARα occupancy of these promoter 
regions in ChIP experiments performed at 5 min intervals, up to 1 h, after RA addition to 
MEF(RARαWT). The specificity of our experimental conditions was checked in the absence 
of antibodies and with the promoter of the control 36B4 gene, which does not contain any 
RARE. 
The proximal promoter region of Cyp26A1, which encompasses the DR5 R1, the TATA 
box and the transcription start site, was already occupied to some extent by RARα in the 
absence of RA (Table 1). Then the level of DR5 R1 bound to RARα started to increase at 30 
min after RA addition (Fig. 4c), peaked at 40-55 min, decreased by 60 min and came back 
close to the initial values at 2h. No additional variations were detected up to 16 h 
(Supplemental information, Fig. S1c). In contrast, at the distal R2 region, RARα was hardly 
detected in the absence of RA (Table 1), but was markedly recruited following RA addition 
with a peak at 40-55 min (Fig. 4b and Supplemental information, Fig. S1c).  
It is interesting to note that the corepressor SMRT was bound to R1 in the absence of 
RA, in line with the presence of RARα in this region, and dissociated rapidly after RA 
addition (Fig. 4c). However SMRT could not be detected at R2 consistent with the absence of 
RARα (Fig. 4b).  
As RARα binds TFIIH after RA addition, we also examined the recruitment of TFIIH in 
ChIP experiments performed with antibodies against its cyclin H, cdk7 or XPB subunits. In 
the absence of RA, the three TFIIH subunits already occupied R1, but could not be 
significantly detected at R2 (Table 1 and Fig. 4d,e). In response to RA, the levels of R1 and 
R2 bound to TFIIH increased markeddly and reached a peak at 40-50 min (Fig. 4d,e), which 
was concomitant with that of RARα. To show that TFIIH and RARα are present in the same 
complex on the promoter, MEF(RARαWT) were subjected to sequential ChIP (reChIP) 
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experiments, first with anti-RARα and then with anti-TFIIH antibodies. Both R1 and R2 
regions were specifically enriched at 45 min (Fig. 4f,g, lanes 5), demonstrating that TFIIH 
and RARα form a complex on chromatin in a RA-dependent manner. Finally, ChIP 
experiments were performed with antibodies recognizing specifically RARα phosphorylated 
at S77, the cdk7 site. At 45 min following RA addition, RARα recruited to the R1 and R2 
regions of the CYP26A1 promoter was phosphorylated at S77 (Fig. 4f,g, lanes 6). Altogether, 
these results indicate that RARα bound at the promoter is associated with TFIIH and 
phosphorylated at S77. Note that RNA polII was also recruited to R1 and R2 in parallel to 
RARα and TFIIH (Fig. 4b,c).  
 
The phosphorylation cascade initiated at S369 and ending at S77 controls the 
recruitment of both RARα and TFIIH to the Cyp26A1 promoter.    
Then we investigated whether phosphorylation is required for promoter recruitment of 
RARα, in ChIP experiments performed with MEF(RARαS369A) and MEF(RARαS77A) 
(Fig. 4h,i). RARαS369A which does not interact with TFIIH and therefore cannot be 
phosphorylated at S77 in response to RA, was not recruited to R1 and R2. RARαS77A which 
has retained the ability to be phosphorylated at S369 and to interact with TFIIH was also not 
recruited. In both cases, TFIIH was not recruited either (Fig. 4j,k). From these results and 
those above, one can conclude that the last step of the phosporylation cascade, i.e. S77 
phosphorylation is required for the promoter recruitment of RARα-TFIIH complexes.   
 
Activated MSK1 is also recruited to the Cyp26A1 promoter and phosphorylates 
Histones H3 at S10.   
Next we investigated whether MSK1 is recruited to the Cyp26A1 promoter after RA 
addition and whether it phosphorylates histones H3 at S10 (H3S10p), a hallmark of gene 
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transcription activation 22. ChIP assays performed with antibodies specific for phosphorylated 
MSK1 showed that, after RA addition to MEF(RARαWT), the activated kinase is recruited to 
the R1 and R2 regions (Fig. 5b,c), concomitantly with RARα. H3 was phosphorylated at S10 
in the same time slot as assessed in ChIPs with antibodies against H3S10p (Fig. 5b,c). 
Histones H4 were also acetylated at K5, K8 and K12 (Fig. 5b,c). Note that in the context of 
the R1 region, an additional peak of H4 acetylation was observed at 20-25 min (Fig. 5c), 
probably reflecting the recruitment of histone acetylases by RARα already bound to this 
region. Knockdown of MSK1 reduced significantly the accumulation of active MSK1 and 
H3S10 phosphorylation on both R1 and R2, (Fig. 5d,e), confirming that the RA-induced 
phosphorylation of H3 is executed by MSK1 and suggesting an additional role for MSK1 in 
the activation of RARα-target promoters through histone phosphorylation. Interestingly it 
also blocked the recruitment of RARα and TFIIH (Fig. 5f,g). Moreover, in SKBR3 cells 
which are defective in MSK1 activation compared to MCF7 cells, RARα and TFIIH 
recruitment to R2 and R1 remained low and unchanged, irrespective of the RA treatment 
duration (Fig. 5h,i).  
 
Phosphorylated RARα controls the formation of a bridge between the R1 and R2 
regions of the Cyp26A1 promoter. 
According to several recent studies, DNA looping may juxtapose promoter DNA with 
enhancer elements that lie far upstream 27. Given that, in response to RA, RARα is recruited 
to both the R1 and R2 regions of the CYP26A1 promoter, in association with TFIIH and RNA 
PolII, we raised the hypothesis that RARα would bridge R1 and R2 to form an 
enhanceosome. To demonstrate the existence of such a gene looping, we performed ChIP-
loop assays 28, which combine Chromosome Conformation Capture (3C) with chromatin 
immunoprecipitation (Fig. 6a).  
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In MEF(RARαWT) RA-treated for 50 min, PCR amplification of non digested 
immunoprecipitated material with primers corresponding to R1 and R2 (Fig. 6a2), produced a 
1930 bp fragment (Fig. 6b, lane 2). Upon digestion with PvuII, which cuts twice between R1 
and R2 (Fig. 6a4), a new 1300 bp band was generated (Fig. 6b, lanes 8-15), which represents 
loss of a 630 bp fragment and religation of the R1 and R2 regions that remained in close 
proximity due to bridging complexes. Religation was confirmed by PCR amplification with 
primers on both sides of the junction that generated a 360 bp fragment instead of a 1000 bp 
one (Fig.6b, lower panel). The 1300 and 360 bp fragments were detected at 30 min up to 60-
75 min following RA addition (Fig. 6b,c), when RARα was recruited to both R1 and R2 in 
ChIP experiments (Fig. 4). Similar results were obtained when immunoprecipitation was 
performed with TFIIH or RNA polII antibodies (Fig.6c). Collectively, these results indicate 
that the R1 and R2 regions become juxtaposed in response to RA, through the recruitment of 
complexes involving RARα as well as TFIIH and RNA PolII. 
In contrast, in MEF(RARαS77A), only a transient and delayed bridge was detected 
when ChIP Loop experiments were performed with RARα or TFIIH antibodies. No bridging 
occured when immunoprecipitation was performed with RNA polII antibodies (Fig. 6b, lanes 
16-28 and Fig. 6c, lanes 10-18). Collectively, such results indicate that efficient looping relies 
on the promoter recruitment of the phosphorylated form of RARα.  
 
Activated MSK1 and RARα phosphorylation also control the RA induction of 
other target genes promoters such as the RARβ2 gene. 
In MEFs, other well known RA-target genes such as the RARβ2 gene are also inhibited 
upon knockdown of MSK1 or knockout of the three RARs. The RA induction of RARβ2 was 
reestablished upon reexpression of RARαWT, but not of RARαS77A or RARαS369A 
(Supplementary information, Fig. S1a). The RARβ2 gene promoter contains only one DR5 
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RARE at position -60 29 and ChIP experiments (Supplemental information, Supplemental 
Table 1 and Fig. S1) gave results that were very similar to those obtained above for the 
proximal R1 region of the Cyp26A1 promoter. Indeed, prior to RA treatment, the DR5 region 
was already occupied by RARα, TFIIH, and the corepressor SMRT. After RA addition, the 
corepressor SMRT dissociated rapidly but the levels of DR5 region bound to RARα, TFIIH 
and RNA polII increased markedly with a peak at 45-55 min. DNA-recruited RARα was 
associated with TFIIH and phosphorylated at S77, and mutation of the phosphorylation sites 
abrogated the recruitment of RARα-TFIIH complexes. Phosphorylated MSK1 was also 
recruited to the promoter which became phosphorylated at H3S10 and acetylated at 
H4K5;8;12. Finally knockdown of MSK1 abrogated H3S10 phosphorylation and the 
recruitment of RARα and TFIIH. These results confirm that MSK1 is the upstream signal 
promoting phosphorylation cascades targeting H3S10 and RARα and subsequently the 
recruitment of RARα-TFIIH complexes to promoters.  
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DISCUSSION 
In this manuscript, we demonstrated that the activation of the p38MAPK pathway by 
RA 15,17 is required for the induction of RARα target genes. We outlined a new paradigm in 
which, in vivo, RA induces a phosphorylation cascade, starting with the rapid activation of 
p38MAPK, leading to MSK1 activation, phosphorylation of RARα and Histone H3 and 
finally to promoter recruitment of RARα and the transcription machinery (Fig. 7). To our 
knowledge, this is the first report of a coordinated phosphorylation cascade induced by RA 
and coupled to promoter activation. It was unexpected and shed light on a new level of 
complexity in the fine-tuning of RARα-mediated transcription. 
The mechanism of activation of p38MAPK/MSK1 is out of the topic of this report, but 
involves very likely a non-genomic activation event 30, similar to that described for steroid 
receptors 22,31 and requiring liganded RARα. One of the targets of MSK1 is RARα which 
becomes rapidly phosphorylated at S369 located in the LBD and we found that 
phosphorylation of this residue is critical for the recruitment of TFIIH and the subsequent 
phosphorylation of the NTD at S77 by cdk7. Given that S369 is located in close proximity of 
the cyclin H binding domain24, we propose that, in vivo, phosphorylation of this residue by 
MSK1 propagates a signal to the cyclin H binding surface, allowing the recruitment of CAK 
within TFIIH, in line with our previous in vitro results 32. Ultimately, the consequence of the 
last step of this cascade, i.e. S77 phosphorylation, is to anchor RARα-TFIIH complexes to 
target promoters. Additional investigations are required to determine how S77 
phosphorylation affects the binding of RARα to response elements. Interestingly, in the 
context of a promoter with two RAREs, a proximal and a more distal one, as exemplified with 
the Cyp26A1 promoter, phosphorylated RARα bridges both RAREs, in association with 
TFIIH and RNA PolII. Whether other chromatin remodeling and/or transcription factors are 
also involved to form an enhanceosome 27 awaits further studies.  
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The other novelty of this study is that MSK1 is recruited to RARα-target promoters in 
the active phosphorylated form, leading to increased phosphorylation of S10 on H3. A similar 
mechanism was recently reported for the regulation of other nuclear receptor target genes 22. 
Then the question is how MSK1-mediated phosphorylation of H3 contributes to RARα-target 
genes induction. One possibility is that phosphorylated H3S10 is a chromatin mark 
accounting in cooperation with other histones modifications for the dissociation of repressive 
complexes and/or the recruitment of chromatin-remodelling complexes 22. Finally, how 
MSK1 is recruited to RA-target promoters and whether MSK1 phosphorylates other relevant 
targets will require further investigations 
An unexpected finding in this study is that RARα-TFIIH complexes started to be 
recruited to target promoters only at 30 min after RA addition, while phosphorylation and 
interaction with TFIIH occurred as soon as 5 min. Such a discrepancy suggests that the 
promoters are not accessible yet and that other RA-dependent events such as chromatin 
modifications and remodelling are required. In line with such an hypothesis, our results show 
that histones H4 become acetylated during the first 30 min (Fig. 5). Also unexpected, is that 
the recruitment of RARα-TFIIH complexes was transient and occurred in a narrow time slot 
(from 30 to 60-75 min after RA addition). This might be the basis of the absence of variations 
in the RARα occupancy of the RARβ2 promoter observed by others 33,34. The RA-induced 
phosphorylation cascade targeting RARα and H3 was also transient, suggesting the existence 
of phosphatases that would antagonize the functions of chromatin-tethered kinases  21, MSK1 
and cdk7 within TFIIH.  
Finally, the present study demonstrated that in ERBB2 positive human breast cancer 
SKBR3 cells, the p38MAPK/MSK1 pathway is deregulated, compared to the control MCF7 
cells. Consequently, the phosphorylation cascade and RARα-mediated transcription are 
significantly blunted. Whether the deregulation of the p38MAPK/MSK1 pathway reflects the 
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overexpression of the upstream ERBB2/HER2 oncogene 35,36 awaits further studies. 
Nevertheless it raises the issue of a contribution of the p38MAPK/MSK1 pathway in RA-
induced growth arrest 37 and its specific modulation might be a promising therapeutic strategy 
in the treatment of RA-resistant cancers. Given that the S369 phosphorylation site is shared by 
MSK1 and PKA, our data are also particularly attractive in terms of the synergy between RA 
and cAMP in the treatment of many leukemia  cells 38. 
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METHODS 
Materials 
RA was from Sigma Aldrich Corporation (USA). The synthetic retinoid agonists and 
antagonists were as described 12. Rabbit polyclonal antibodies against RARα, RPα(F), and 
mouse monoclonal antibodies recognizing cyclin H and RARα phosphorylated at S77 or S369 
were previously described 23 ,24 ,32. Monoclonal antibodies against RNA polII phosphorylated 
at S5 in the carboxy terminal repeat domain, cyclin H and acetylated Histones (H4K5;12 and 
H4K5;8;12) were produced by the IGBMC facility. Antibodies against MSK1 and β-actin 
(C11) were purchased from Santa Cruz Biotechnology as well as Polyclonal antibodies 
against RARα (C-20), SMRT (H-300) and the XPB (S-19) and cdk7 (C-19) subunits of 
TFIIH used in the ChIP experiments. Antibodies against P-MSK1 and H3S10p were from 
Cell Signaling and Upstate Biotechnologies Incorporated (Lake Placid, NY, USA), 
respectively.   
 
Cell lines and immunoblotting. 
Mouse embryo fibroblasts with all three RARs deleted, MEF (RARα,β,γ)-/-, were as described 
18. RARα WT, S369A or S77A cDNAs sub cloned from the pSG5 constructs 32 into pMSCV Neo 
plasmid, were reintroduced into these cells by retroviral transfer followed by G418 selection. MCF7 
and SKBR3 human breast cancer cells were cultured under standard conditions. All cell lines were 
treated with RA (10-7M) after 24 hr in medium containing 1% dextran-charcoal-treated FCS. 
Extracts were prepared and immunoblotted as described 39.  
 
RNA isolation and quantitative RT-PCR (qRT-PCR). 
Total RNAs were isolated and subjected to qRT-PCR as described 39. Primer sequences are as 
follows. Mouse 36B4, 5’-GAGGTCACTGTGCCAGCTCA-3’ and 5’-
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GAAGGTGTACTCAGTCTCCA-3’; Mouse CYP26A1, 5’-
GGGCTTACTTTGCAAGAGCA-3’, and 5’-GAAGGCCTCCTCCAAATGGA-3’; 
Human 36B4, 5’-GAAGTCACTGTGCCAGCCCA-3’ and 5’-
GAAGGTGTAATCCGTCTCCA-3’;  Human CYP26A1, 5’-
TCCAGAAAGTGCGAGAAGAG-3’ and 5’-TCTTCAGAGCAACCCGAAAC-3’.   
 
 
Chromatin immunoprecipitation (ChIPs), reChIPs and ChIP-western experiments 
Subconfluent cells were treated with RA (10-7M) and ChIP experiments were performed 
according to the protocol described by Upstate. Control ChIP was performed without 
antibody. In Re-ChIP experiments, complexes were eluted by incubation for 30 min at 37°C 
in 250 μl 95mM NaHCO3 containing 1% SDS, diluted 20 times with Re-ChIP buffer (1% 
Triton X-100, 50 mM Tris-HCl, [pH 7.5], 2mM EDTA, 150 mM NaCl) and subjected again 
to the ChIP procedure. Immunoprecipitated DNA was amplified by qPCR using primer pairs 
designed using the Primer3 software 40: Mouse 36B4, 5’-TTTGCTGTACT GACTCGGTGA-
3’ and 5’-CCTCCCACAACAAAACAACC-3’. Mouse Cyp26A1: R2, 5’-
AAACAGGAGCAGGCTGAACT-3’ and 5’-CGCTGCCACTGTCATATCTT-3’; R1, 5’-
GGTAACTCGGAGCTCTGCAC-3’ and 5’-CCAGGTTACTGCCCACGTTA-3’; Human 
36B4, 5’-AGGACTCCATGTTCCCAAAG-3’ and 5’-
CGCAGCCAATAGACAGGAG-3’; Human Cyp26A1: R1, 5’-
GCGGAACAAACGGTTAAAGA-3’ and 5’-GCAGTACAGGTCCCAGAGCTT-3’; R2, 5’-
GAGTTCACTCGATGTCACG-3’ and 5’- ATCGCGCTGGAGGTAATTCT-3’.   
Primers amplification specificity and efficiency were verified on DNA serial dilutions. 
Occupancy of the promoters was calculated by normalizing the PCR signals from the IP 
samples to the signals obtained from the input DNA.  
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For ChIP-Wersten experiments, the precipitated chromatin complexes were proceeded as 
described 41 and bound proteins were revealed by immunoblotting.   
 
 ChIP loop assay 
Cells cross-linked with formaldehyde were digested with PvuII (New England Biolabs) (600 U, 
overnight, 37°C), religated (4 h at 16°C using T4 DNA ligase) as described in 27 and 
immunoprecipitated with RARα, TFIIH (XPB subunit) or RNA PolII antibodies. Ligation 
frequencies of restriction fragments were analyzed by qPCR with the following primer pairs. 
Primers 1 and 2 (R1 & R2), 5’-AGGTCTCACGATCGATCGGC-3’ and 5’- 
ACGCAGTACAGGTCCCAGAG-3’; Primers 3 and 4 (junction), 5’-
TATTGCAAGGGTTACCGGAC-3’ and 5’-GTAGTAATACCGCCAAGCCG-3’. 
 
 In vitro RARα phosphorylation and detection of Phosphorylated RARα and 
p38MAPK. 
In vitro phosphorylation of purified recombinant RARα expressed in E. coli by the 
purified CAK complex 24 or recombinant active MSK1 (Upstate Biotechnology Incorporated, 
Lake Placid, NY, USA) was performed as previously described 11 followed by 
immunoblotting with antibodies recognizing RARα or RARα phosphorylated at S77 or S369. 
For detection of in vivo phosphorylated RARα, cell extracts were prepared and applied 
to Phosphoprotein Affinity purification columns (PhosphoProtein Purification System, 
Qiagen S.A.) according to manufacturer-supplied instructions. After washing, column eluates 
containing protein peaks were concentrated and analyzed by immunoblotting. Phosphorylated 
p38MAPK was detected by using a Phospho p38MAPK (Thr(P)-180/Tyr(P)-182) ELISA kit 
(Biosource Invitrogen Corporation).   
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Short Interfering (si) RNA. 
The smartpool small interfering RNA against human MSK1 (M-004665-01), mouse MSK1 
(L-040751-00) or mouse p38MAPK (M-040125-00) were purchased from Dharmacon (Lafayette, 
CO) as well as the control non targeting siRNA pool (D-OO1206-13). SiRNAs (50 nM) were 
transfected by using Lipofectamine 2000 (Invitrogen) according to manufacturer’s protocol. Then 
cells were vehicle- or RA-treated 48h post transfection. 
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FIGURE LEGENDS 
Figure 1. In vivo, RA activates the p38MAPK/MSK1 pathway. 
(a) Analysis of p38MAPK activation in MEF WT treated with RA (10-7M), synthetic 
retinoids specific for RARα (BMS 753, 10-7M), RARγ (BMS 961, 10-7M), RARβ (BMS 493, 
10-7M) or a RARα antagonist (BMS 614, 10-6M). The results are an average of three 
experiments that agreed within 15%. (b) Same experiments with MEFs WT, RAR (α,β,γ)−/− 
or reexpressing RARαWT in a RAR(α,β,γ) nul background. Western blots show the 
expression of RARα in the different cell lines (right panel). (c) p38MAPK activation in 
MCF7 and SKBR3 cells treated with RA (10-7M). (d)  Immunoblotting analysis of 
active/phosphorylated MSK1 in extracts from RA-treated MCF7 cells applied onto 
Phosphoprotein Affinity columns. (e) Comparison  of MSK1 activation/phosphorylation in 
RA-treated MEFs, MCF7 and SKBR3 cells (f) Knockdown of p38MAPK with siRNAs 
abrogates the activation of MSK1 in RA-treated MEFs.  
 
Figure 2. RA activated MSK1 phosphorylates RARα and induces interaction with 
and phosphorylation by CAK within TFIIH.  
(a) Schematic representation of the RARα1 protein with the functional domains and 
phosphorylation sites. (b) In vitro phosphorylation of purified bacterially expressed RARα 
with highly purified CAK and active recombinant MSK1, was analyzed by immunoblotting 
with antibodies recognizing RARα phosphorylated at S369 or S77. (c) Kinetics of 
RARα phosphorylation in RA-treated MCF7 cells after Phosphoprotein Affinity purification. 
(d) Immunoblots showing after Phosphoprotein Affinity purification, that RA induces RARα 
phosphorylation at S369 and S77 in MCF7 cells but not in SKBR3 cells. (e) Knockdown of 
MSK1 abrogates the RA-induced phosphorylation of RARα in MCF7 cells. (f) Immunoblots 
showing the reexpression of RARαWT, S369A and S77A in MEF(RARα,β,γ)-/-. (g) RARα 
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phosphorylation in extracts from MEF(RARαWT), (RARαS369A) and (RARαS77A) after 
Phosphoprotein Affinity purification. (h)  ChIP-Western experiments performed with 
MEF(RARαWT), MEF(RARαS77A) and MEF(RARαS369), treated with RA for the 
indicated times. The complexes immunoprecipitated with RARα antibodies were analyzed by 
immunoblotting as indicated.  
 
Figure 3. MSK1 is required for the RA-induced activation of the Cyp26A1 gene. 
(a) The RA-induced expression of the CYP26A1 gene which is abolished in 
MEF(RARα,β,γ)-/- , is rescued upon reexpression of RARαWT, but not of RARαS369A or 
S77A, as monitored by qRT-PCR. (b) The CYP26A1 gene is activated in MCF7 but not in 
SKBR3 cells in response to RA, in qRT-PCR experiments. (c, d) Knockdown of MSK1 
inhibits the RA-induced expression of CYP26A1 in MEFs and MCF7 cells 
 
Figure 4. Phosphorylation controls the recruitment of RARα and TFIIH to the 
CYP26A1 gene promoter. 
(a) Schematic representation of the promoter regions of the CYP26A1 gene, with the 
primer pairs used for qPCR amplification. (b, c) Kinetic ChIP experiments performed with 
RA-treated MEF(RARαWT) and determining the recruitment of RARα,  RNA PolII and 
SMRT to the R1 and R2 promoter regions. Values correspond to a representative experiment 
among 5. (d, e) Kinetic ChIP experiments determining the recruitment of the cdk7, cyclin H 
and XPB subunits of TFIIH to R1 and R2. (f, g) ChIP and reChIP experiments performed 
with the indicated antibodies, showing that, at 45 min following RA addition, DNA bound 
RARα is associated with TFIIH and phosphorylated at S77. Results are an average of 2 
experiments that agreed within 20%. (h-k) Kinetic ChIP experiments determining the 
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recruitment of RARα and the XPB subunit of TFIIH at R1 and R2 in MEF(RARαWT), 
(RARαS369A) and (RARαS77A). 
 
Figure 5. MSK1 is recruited to the Cyp26A1 promoter and phosphorylates 
histones. 
(a) Schematic representation of the CYP26A1 promoter. (b, c) Kinetic ChIP 
experiments showing that after RA addition, P-MSK1 is recruited to R1 and R2 and that 
H3S10 become phosphorylated and H4K5;8;12 acetylated. (d-g) Knockdown of MSK1 with 
siRNAs abrogates H3S10 phosphorylation and the recruitement of RARα and TFIIH to R1 
and R2. (h, i) Kinetic ChIP experiments showing the recruitment of RARα and the XPB 
subunit of TFIIH to R2 and R1 in RA-treated MCF7 and SKBR3 cells. Values correspond to 
a representative experiment among 3.  
 
Figure 6. ChIP-Loop assay showing that RARα bridges the R1 and R2 regions of 
the CYP26A1 promoter.  
(a) Schematic representation of the CYP26A1 promoter with R1 and R2, the PvuII 
restriction sites and the primers used to amplify the whole promoter (primers 1 and 2) or the 
junction (primers 3 and 4). (b) ChIP-Loop assay performed with MEF(RARαWT) and 
MEF(RARαS77A) showing that RARα phosphorylated at S77 controls the formation of a 
bridge between R1 and R2. Chromatin from control and RA-treated cells was 
immunoprecipitated with RARα antibodies without or with prior PvuII digestion-ligation of 
DNA, as indicated. Then qPCR was performed with primer pairs 1 and 2 (upper panels) or 3 
and 4 (lower panels). (c) Qame as in (b) with RARα, TFIIH and RNA polII antibodies. 
 
Figure 7. Recapitulation of the phosphorylation cascade induced by RA.  
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In response to RA, p38MAPK and the downstream protein kinase MSK1 are activated. 
MSK1 phosphorylates the LBD of RARα at S369, allowing the docking of cyclin H within 
TFIIH and the formation of a RARα/TFIIH complex. Then the cdk7 subunit of TFIIH 
phosphorylates the NTD of RARα at S77. MSK1 is also recruited and phosphorylates H3S10. 
Finally, RARα phosphorylated and associated with TFIIH is recruited to response elements 
located in the promoter of target genes.  
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TABLE 1 
Chromatin immunoprecipitation experiments (ChIP) determining the basal recruitment of RARα  
and the XPB subunit of TFIIH to R1 and R2 in the different rescue MEF lines. Values (% of the 
inputs) are the mean ±SD of triplicates performed on three separate chromatin preparations. Data 
were analyzed using Microsoft Excel 2002. Unpaired Student’s T test for pair-wise comparison 
was used to determine the statistically significant difference in RARα or TFIIH recruitment versus 
the 36B4 signals or the signals obtained in the absence of antibody. A p-value less than 0.5 (*) 
denotes a statistical significance. 
 
MEF 36B4 Cyp26A1-R2 Cyp26A1-R1 
 Control Ab RARα Control Ab RARα Control Ab RARα 
       
RARα WT 0.024±0.003 0.045±0.012 0.036±0.010 0.103±0.021 0.036±0.001 0.807±0.277* 
       
RARαS369A ND ND 0.121±0.015 0.211±0.027 0.121±0.016 0.700±0.317* 
       
RARαS77A ND ND 0.036±0.003 0.075±0.006 0.036±0.003 0.273±0.175 
       
 Control AbTFIIH Control AbTFIIH Control AbTFIIH 
       
RARαWT 0.156±0.012 0.121±0.009 0.146±0.049 0.131±0.032 0.161±0.081 0.659±0.122* 
       
RARαS369A ND ND 0.226±0.051 0.256±0.0339 0.266+0.09 0.831±0.336* 
       
RARαS77A ND ND 0.165±0.057 0.205±0.058 0.176±0.094 1.026+0.049* 
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